Breaking News Headlines Today

News from Cardiovascular News

Stay current with all the latest and breaking news from Cardiovascular News. Compare headlines and media bias behind news outlets on stories breaking today.

We’ve discovered 85 headlines written by Cardiovascular News during the past 3 months.

Cardiovascular News’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to Cardiovascular News. You can read more about how we’ve determined Cardiovascular News’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.

Information about Cardiovascular News

Where is Cardiovascular News located?Cardiovascular News's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Cardiovascular News News

Technology · Indianola

FIRST HEART VALVE REPLACEMENT USING NEW ROBOTIC SURGERY TECH AND ARTIFICIAL VALVE DESIGNED BY CORCYM

86% Center coverage: 7 sources

/PRNewswire/ -- Corcym today announced that its Perceval Plus® sutureless aortic heart valve was used in a First-Ever robotic aortic valve replacement, through...See the Story

FTC · Irvine

JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition

72% Center coverage: 7 sources

IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company’s proposed acquisition by Edwards Lifesciences.See the Story

Medical

Global study finds heart failure drug spironolactone fails to lower cardiovascular risk in dialysis patients

100% Center coverage: 1 sources

A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.See the Story

Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure Trial

What You Should Know: – Reprieve Cardiovascular, a clinical-stage company secures $61M in Series B funding led by Deerfield Management and included participation from several other investors, such as Arboretum Ventures, Lightstone Ventures, and an undisclosed strategic investor. – The funding round, which combines equity investment with a debt facility will be used to support the rapid execution of the global FASTR II pivotal clinical trial and…See the Story

Image-guided crossing and re-entry system used for first time in coronary CTO trial - Cardiovascular News

Simpson Interventions has announced that its Acolyte image-guided crossing and re-entry catheter system has been successfully used to treat the first patients in the Acolyte study, a pivotal investigational device exemption IDE clinical trial designed to assess the safety and effectiveness of the system in treating coronary chronic total occlusions (CTOs) with persistent symptoms following medical therapy. “Our team is thrilled to have successfu…Atlanta, Georgia · Atlanta See the Story

Heartflow raises more than US$364 million through initial public offering - Cardiovascular News

Heartflow, a developer of artificial intelligence (AI) tools for the diagnosis of coronary artery disease, has been publicly listed on the Nasdaq stock exchange, raising more than US$364.2 million through an initial public offering (IPO). The company offered 19,166,667 shares of its common stock at a public offering price of US$19 per share, which began trading on the Nasdaq Global Select Market on 8 August under the ticker symbol HTFL. The comp…Artificial Intelligence · New York Read Article

APC Cardiovascular acquires Precision Surgical - Cardiovascular News

APC Cardiovascular has announced the acquisition of Precision Surgical, a specialist in high-quality surgical instruments and retractor systems. Founded in 2007, Precision Surgical has earned a reputation as one of the UK’s leading suppliers of surgical devices to the NHS and private hospitals, a press release from APC Cardiovascular states. Its portfolio spans all major surgical specialities, with particular expertise in microsurgery, ear, nose…United Kingdom · United Kingdom Read Article

Wearable patch may speed up diagnosis of atrial fibrillation after cardiac surgery - Cardiovascular News

The use of a wearable electrocardiogram (ECG) monitor for up to 14 days after cardiac surgery may improve the detection of postoperative atrial fibrillation (poAF), potentially speeding up the detection of cases which may have gone unseen until up to three months’ follow-up, researchers have shown. Preliminary results of a 100-patient study involving the use of the Vivalink wearable ECG patch following cardiac surgery procedures at Brigham and W…Boston, Massachusetts · Boston Read Article

Gentuity and GE HealthCare Collaborate to Improve Availability of Imaging Systems - Cardiovascular News

Gentuity has announced an agreement with GE HealthCare to collaborate on commercial activities. The collaboration is intended to enhance the availability, adoption, and functionality of highly complementary imaging solutions for interventional cardiology, the companies have announced in a press release. As part of the agreement, Gentuity and GE HealthCare aim to jointly pursue co-marketing initiatives and technical integration of their respectiv…United States · United States See the Story

Total artificial heart system gains entry to US FDA advisory programme - Cardiovascular News

Bivacor has announced that its total artificial heart (TAH) system has been accepted into the US Food and Drug Administration’s (FDA) total product life cycle (TPLC) advisory programme—known as the TAP programme. The programme is designed to accelerate the development and patient access to high-impact medical technologies. Entry into the programme provides Bivacor with proactive, strategic engagement with the FDA throughout the entire product li…United States · United States Read Article

ShortCut leaflet splitting device granted add-on payment designation by CMS - Cardiovascular News

ShortCut Pi-Cardia has announced that the Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) for the ShortCut leaflet splitting device, effective 1 October 2025. The NTAP designation recognises ShortCut as a breakthrough technology that addresses a critical unmet need in valve-in-valve transcatheter aortic valve implantation (TAVI) by enabling treatment for patients at risk of coronary obstruction.…United States · United States Read Article

News from Cardiovascular News